OLD GREENWICH, Conn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) formerly, Hudson Global, Inc. (Nasdaq: HSON and HSONP) (“Star” or the “Company”), a diversified holding company, announced today that its management team will present and host one-on-one meetings with investors at Noble Capital Markets Emerging Growth Virtual Conference, which will take place from February 4-5, 2026. Star’s main presentation is scheduled for Thursday, February 5 at 2:30pm ET. Investor ...

New York, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aether Holdings, Inc. (NASDAQ: ATHR) (“Aether” or “the Company”), an emerging financial technology holding company developing data-driven platforms and media assets for investors, today announced the Company will ring the Nasdaq Stock Market Closing Bell on Friday, January 30, 2026. The event, led by Chief Executive Officer Nicolas Lin alongside other members of the Company’s management team, will commemorate Aether’s initial public offering and commencement of tr ...

CONROE, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- via IBN -- Olenox Industries Inc. (NASDAQ: OLOX) ("Olenox Industries" or the "Company"), today announced that it has executed a non-binding Letter of Intent to acquire the midstream business and transportation assets of CPE Gathering MidCon, LLC ("CPE Gathering") from Vivakor, Inc. (OTC: VIVK), owner and operator of the Omega pipeline system, an integrated crude-oil gathering, transportation, terminaling and pipeline connection platform serving the Oklahoma S ...

Core Viewpoint - Gran Tierra Energy Inc. has reported significant operational achievements, including record production levels and successful exploration commitments in Ecuador, alongside preliminary financial estimates for 2025, indicating a strong operational performance and growth potential for the company [1][3][4]. Production Achievements - The company achieved an average production of 48,235 boepd in December 2025, marking the highest monthly average in its history [3][4]. - In Ecuador, Gran Tierra reached a daily production rate of 10,000 bopd during the fourth quarter of 2025, with current production rates around 8,800 bopd [4]. - The Conejo wells (A-1 and A-2) continue to produce approximately 2,700 bopd, with individual IP60 rates of 1,921 bopd and 1,317 bopd respectively [4]. Exploration and Development - All exploration commitments in Ecuador have been fulfilled, highlighted by successful discoveries at Conejo, contributing to a combined IP60 rate of approximately 3,238 bopd [4]. - Multiple Field Development Plans (FDPs) have been approved, including the Iguana FDP in Q1 2026 and the Chanangue FDP in Q3 2025, with additional FDPs under review [4]. - The company is advancing its waterflood development program, with a successful injectivity test completed in the Chanangue field, and plans for further injector conversions in 2026 [4]. Financial Estimates - Preliminary unaudited financial data for the year ended December 31, 2025, estimates net debt at approximately $657 million, with capital expenditures ranging from $250 million to $270 million [7]. - Estimated revenue is projected between $590 million to $610 million, with gross profit expected to be in the range of $65 million to $75 million [7]. - Adjusted EBITDA for 2025 is estimated to be between $270 million to $290 million, reflecting strong operational performance despite challenges [7]. Operational Highlights - At Cohembi North, gross production increased to approximately 9,100 bopd, driven by successful drilling and a robust waterflood program [4]. - In Canada, Gran Tierra's Simonette asset continues to show strong performance, with new wells meeting or exceeding expectations, supporting stable production and cash flow [5]. - The company plans to drill four gross development wells in Cohembi during the first half of 2026, enhancing future production capabilities [4].

Key Information - Rathbones Group Plc disclosed a position in The British Land Company Plc, indicating ownership of 368,603 relevant securities, which represents 0.03% of the total [1][3]. Positions of the Discloser - The disclosed interests include 368,603 relevant securities owned and/or controlled, with no short positions reported [3]. Other Information - There are no indemnity or other dealing arrangements related to the relevant securities [12]. - No agreements, arrangements, or understandings regarding options or derivatives were reported [13]. - A Supplemental Form 8 (Open Positions) is not attached [14].

Core Insights - Aprea Therapeutics announced the first unconfirmed partial response (uPR) in a patient from its Phase 1 ACESOT-1051 study, indicating early clinical activity of APR-1051 in treating advanced solid tumors [1][2] Group 1: Clinical Trial Results - The uPR was observed in a patient with PPP2R1A-mutated uterine serous carcinoma, showing a 50% reduction in target lesion size and a decrease in CA-125 levels from 732 to 70 U/mL after treatment with APR-1051 at the 150 mg dose level [2][7] - Earlier cohorts in the ACESOT-1051 study reported stable disease in multiple patients, including a 5% reduction in tumor burden in a patient with HPV-positive head and neck squamous cell carcinoma and a 15% reduction in a patient with FBXW7-mutated colon cancer [3] - The ongoing dose-escalation study is currently enrolling patients in the 220 mg cohort, with plans to increase enrollment of HPV-positive patients [4][6] Group 2: Drug Mechanism and Strategy - APR-1051 is a small-molecule inhibitor of WEE1 kinase, designed to exploit cancer-specific vulnerabilities while minimizing damage to healthy cells [8][9] - The company aims to target cancers with specific genomic alterations, including mutations in PPP2R1A, FBXW7, CCNE1, TP53, and KRAS, reinforcing the potential of APR-1051 as a differentiated treatment option [5] Group 3: Future Outlook - Aprea Therapeutics plans to provide additional updates in the first half of 2026 and complete dose escalation later in the year, indicating ongoing commitment to the development of APR-1051 [5]

Core Viewpoint - Gran Tierra Energy Inc. has initiated an Exchange Offer for its outstanding 9.500% Senior Notes due 2029, allowing Eligible Holders to exchange these for newly issued 9.500% Senior Secured Notes due 2031, with specific terms and conditions outlined in the Exchange Offer Memorandum [1][6]. Exchange Offer Details - The Exchange Offer involves the exchange of US$716.34 million of Existing Notes for New Notes, with an Early Participation Premium of US$50 for those who participate before the Early Participation Deadline [2][10]. - Eligible Holders who tender their Existing Notes by the Early Participation Deadline will receive a Total Consideration of US$1,000 per US$1,000 principal amount, which includes the Early Participation Premium [10][11]. - The Total Consideration will be paid in a combination of cash and New Notes, with accrued interest paid in cash on the respective settlement dates [15][11]. Important Dates - The Exchange Offer commenced on January 29, 2026, with the Early Participation Deadline set for February 11, 2026, and the Expiration Deadline on February 27, 2026 [8][7]. - The Early Settlement Date is expected to be February 18, 2026, and the Settlement Date is anticipated to be March 2, 2026 [8][7]. Proposed Amendments - Alongside the Exchange Offer, the Company is soliciting consents from Eligible Holders to amend the Existing Indenture, which includes eliminating restrictive covenants and releasing collateral securing the Existing Notes [6][16]. - The amendments require the consent of at least 66-2/3% of the aggregate principal amount of Existing Notes outstanding [6][8]. Cash Consideration Structure - The cash consideration for the Total Consideration will start at US$110 million if 80% of the Existing Notes are tendered, increasing by US$750,000 for each additional 1% tendered, up to a maximum of US$125 million if 100% are tendered [11][12]. - The distribution of cash consideration per US$1,000 of Existing Notes will vary based on the total amount tendered, with specific examples provided for different participation levels [13][11]. Eligibility and Participation - The Exchange Offer is available to holders who qualify as "qualified institutional buyers" in the U.S. and "accredited investors" in Canada, with specific eligibility requirements outlined [18][21]. - Eligible Holders must complete an eligibility letter to participate in the Exchange Offer and receive the Exchange Offer Memorandum [18][21].

Core Insights - SeaStar Medical Holding Corporation is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [1][3] - The company will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 5, 2026 [1] - SeaStar Medical's QUELIMMUNE (SCD-PED) therapy is the first commercial product based on its patented Selective Cytopheretic Device (SCD) technology, approved by the FDA in 2024 [3] Company Overview - SeaStar Medical is a commercial-stage healthcare company targeting critically ill patients with organ failure [3] - The QUELIMMUNE (SCD-PED) therapy is the only FDA-approved treatment for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [3] - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process and better reimbursement dynamics [3] Clinical Trials - The company is conducting the NEUTRALIZE-AKI pivotal trial for its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT) [3] - This condition affects over 200,000 adults in the U.S. annually and currently has no effective treatment options [3]

Core Viewpoint - Aprea Therapeutics has announced a private placement of common stock and warrants, aiming to raise approximately $5.6 million to support its ongoing clinical studies and general corporate purposes [1][2][3] Group 1: Offering Details - Aprea will sell a total of 6,288,857 shares of common stock (or pre-funded warrants) along with warrants to purchase an equal number of shares, at an effective offering price of $0.89 per share [1][2] - The warrants will have an exercise price of $0.765 per share, exercisable immediately upon issuance, and will expire two years from the effectiveness date of the registration statement [1][2] Group 2: Use of Proceeds - The gross proceeds from the offering are estimated to be around $5.6 million before deducting fees and expenses, which will be used for general corporate purposes and research and development expenses [2] Group 3: Clinical Development Focus - The financing is intended to support the ongoing ACESOT-1 dose-escalation study of APR-1051, a WEE1 kinase inhibitor, with the goal of optimizing dosage and patient population [3] - The addition of more patients to the study is expected to enhance the dataset for safety and early efficacy, potentially leading to significant clinical milestones [3] Group 4: Company Overview - Aprea Therapeutics is focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells [6] - The company's lead programs include APR-1051 and ATRN-119, both of which are in clinical development for solid tumor indications [7]

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. (“Purchaser”), an indirect wholly owned subsidiary of Cycle Group Holdings Limited (“Cycle”). January 29, 2026 Dear Applied Therapeutics Stockholders, As announced on December 11, 2025, ...